[New possibilities in therapy of ocular inflammation in rheumatic diseases].

Abstract

This review is devoted to the potential application of genetically engineered biological drugs of different classes in the treatment of main forms of uveitis and other types of non-infectious ocular inflammation in immunoinflammatory rheumatic diseases. The article presents the results of studies demonstrating the influence of interleukin-17 inhibitor secukinumab on the course of uveitis in spondylarthritis, shows the possibilities of treating uveitis in juvenile idiopathic arthritis with inhibitors of interleukin-6, co-stimulation of T-lymphocytes. Inhibition of interleukin-1 is considered an effective method of influencing the ocular inflammation in monogenic autoinflammatory syndromes and Behcet's disease. Rituximab is considered as an option for immunosuppressive therapy of non-infectious uveitis and scleritis.

• Authors: I Yu Razumova, A A Godzenko
• Journal: Vestnik oftalmologii (Vestn Oftalmol) Vol. 138 Issue 6 Pg. 108-114 ( 2022) ISSN: 0042-465X [Print] Russia (Federation)
• Vernacular Title: Novye vozmozhnosti terapii vospaleniya glaz pri revmaticheskikh zabolevaniyakh.
• PMID: 36573954 (Publication Type: Review, English Abstract, Journal Article)

Topics

• Humans
• Inflammation (drug therapy)
• Uveitis (diagnosis, drug therapy, etiology)
• Vision Disorders
• Rheumatic Diseases (complications, drug therapy)
• Scleritis (diagnosis, drug therapy, etiology)